This is a working overview of GHRH analog, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-29. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Zverev is a baseline counterpuncher who relies on his massive serve and powerful backhand. He is able to hit strong groundstrokes to open the court, and finish points effectively at the net. Although his height slows him down on the court, it also adds to his reach and gives him the ability to get more balls back in play. Novak Djokovic has commented, "He moves well for his height." His backhand, in particular, is regarded as his strength and one of the best in the game. He can generate a lot of power off it with high accuracy, and his ability to absorb pace makes it one of the best shots in the modern game for both attack and defense. He often uses a semi-open stance and employs a western grip on his forehand. He has a continental-eastern grip on his backhand. Zverev can also slice his backhands that require a low centre of gravity, despite his height. He is often criticized for being too passive in the big moments. With Zverev's height of 1.98 metres (6 ft 6 in), he can generate big serves at 220 kilometres per hour (140 mph) or faster at sharper angles than shorter players. The year Zverev first broke into the top 20, he was still not one of the better servers on tour, ranking just 38th in serve rating. This was well behind him ranking 18th in return rating, showing that his return game was much stronger than his serving. By 2018, he had improved in both categories, ranking 19th in serve rating and 8th in return rating. Zverev excels in particular at hitting a high percentage of first serves in, landing 64.2% in 2018.
The influx of refugees troubled the Cossacks, not only because of the increased demand for food but also because their large number meant the Cossacks could not absorb them into their culture by way of the traditional apprenticeship. Instead of taking these steps for proper assimilation into Cossack society, the runaway peasants spontaneously declared themselves Cossacks and lived alongside the true Cossacks, laboring or working as barge-haulers to earn food. Divisions among the Cossacks began to emerge as conditions worsened and Mikhail's son Alexis took the throne. Older Cossacks began to settle and become prosperous, enjoying privileges earned through obeying and assisting the Muscovite system. The old Cossacks started giving up the traditions and liberties that had been worth dying for, to obtain the pleasures of an elite life. The lawless and restless runaway peasants who called themselves Cossacks looked for adventure and revenge against the nobility that had caused them suffering. These Cossacks did not receive the government subsidies that the old Cossacks enjoyed, and had to work harder and longer for food and money.
Very few drugs are known to effectively inhibit SARS‑CoV‑2. Masitinib was found to inhibit SARS-CoV-2 main protease, showing a greater than 200-fold reduction in viral titres in the lungs and nose of mice, however it is not approved for the treatment of COVID-19 in humans. In December 2021, the United States granted emergency use authorisation to Nirmatrelvir/ritonavir for the treatment of the virus; the European Union, United Kingdom, and Canada followed suit with full authorisation soon after. One study found that Nirmatrelvir/ritonavir reduced the risk of hospitalisation and death by 88%. COVID Moonshot is an international collaborative open-science project started in March 2020 with the goal of developing an un-patented oral antiviral drug for treatment of SARS-CoV-2.
Sources: en.wikipedia.org
== Discography == OutKast - Speakerboxx/The Love Below Co-wrote "Church" & "Bust" Performed on "I Like The Way You Move" "Church", "Bust", "Unhappy", "Ghetto Musick", "Happy Valentine"s Day", "Bowtie" and "War" Outkast - Idlewild Wrote & Performed "Mutron Angel" Co-Wrote & Performed on "The Train" Co-Wrote & Performed on "A Bad Note" Joi - Tennessee Slim Is The Bomb Performed on "Co Stars" Outkast - Aquemini Co-wrote "Liberation" Performed on various tracks Khujo Goodie - The Man Not The Dawg Produced, co-wrote & performed on "Pimpz & Hoz" & "Shawtly" Pink - "Can"t Take Me Home" Performed on "You Make Me Sick" re-mix Raphael Saadiq - Live at the House Of Blues Performed on all tracks Big Gipp - Mutant Mindframe Performed on "Creeks" Killa Mike - Monster Performed on "A.D.I.D.A.S." and Monster Joi - Amoeba Cleansing Syndrome Performed on "U Turn Me On" OutKast - Big Boi & Dre Present Outkast Greatest Hits Performed on "The Whole World" OutKast - Atliens Co-wrote "You May Die" Performed on various tracks Goodie Mob - Still Standing Produced & co-wrote "Just About Over", performed on "Just About Over" & "They Don't Dance No Mo", "I Feel Responsible" and "The Walk" Soundtrack - Scooby Doo Original Movie Soundtrack Performed on "Land Of A Million Drums" Backbone - "Concrete Law" Performed on "Yes Yes Ya"ll", "Believe That" and "Under Streetlights" Soundtrack - Tomb Raider Original Movie Soundtrack Performed on "Speed Ballin" Soundtrack - Ali Original Movie Soundtrack Performed on "Set Me Free" & "Death Letter" Dungeon Family - Even In Darkness Performed on "Follow The Light" and "Rollin" Slimm Calhoun - "The Skinny" Performed on "Dirt Work", "Current Events" and "Red Clay" OutKast - Stankonia Performed on various tracks Witch Doctor - Witch Doctor Performed on "Goo Goo Eyes" Lil Will - Wrote, co-produced, & performed on "I Still Love You", performed on "Georgia Girl" Soundtrack - Shaft Performed on "Automatic" TLC - Fanmail Performed on "Silly Ho" Cool Breeze - East Points Greatest Hits Co-wrote "Ghetto Camelot" Performed on "Ghetto Camelot", "Creatine", "East Pointed" and "The Field" Soundtrack - Light It Up Original Movie Soundtrack Performed on "High Schoolin" Macy Gray - Macy Gray On How Life Is Performed on "Git Up, Git Out, Git Something"
Pherokine-2 and -3: Two Drosophila molecules related to pheromone/odor-binding proteins induced by viral and bacterial infections. Eur J Biol. 2003; 270: 3398-3407. 34. Liu GX, Ma HM, Xie YN, Xuan N, Xia G, Fan ZX, et al. Biotype characterization, developmental profiling, insecticide response and binding property of Bemisia tabaci chemosensory proteins: role of CSP in insect defense. PLoS ONE 2016; 11: e0154706. 35. Nomura A, Kawasaki K, Kubo T, Natori S. Purification and localization of p10, a novel protein that increases in nymphal regenerating legs of Periplaneta americana (American cockroach). Int J Dev Biol. 1992; 36: 391-398. 36. Jin X, Brandazza A, Navarrini A, Ban L, Zhang S, et al. Expression and immunolocalization of odorant-binding and chemosensory proteins in locusts. Cell Mol Life Sci. 2005; 62: 1156-1166. 37. Maleszka J, Forêt S, Saint R, Maleszka R. RNAi-induced phenotypes suggest a novel role for a chemosensory protein CSP5 in the development of embryonic integument in the honeybee (Apis mellifera). Dev. Genes Evol. 2007; 217: 189-196. 38. Ozaki M, Wada-Katsumata A, Fujikawa K, Iwasaki M, Yokohari F, Satoji Y, Nisimura T, Yamaoka R. Ant nestmate and non-nestmate discrimination by a chemosensory sensillum. Science 2005; 309: 311-314. 39. Rodriguez PA, Stam R, Warbroek T, Bos JI. Mp10 and Mp42 from the aphid species Myzus persicae trigger plant defenses in Nicotiana benthamiana through different activities. Mol Plant Microbe Interact. 2014; 27: 30-39. 40. Wanner KW, Willis LG, Theilmann DA, Isman MB, Feng Q, Plettner E.
=== Sphingomyelin hydrolysis === Hydrolysis of sphingomyelin is catalyzed by the enzyme sphingomyelinase. Because sphingomyelin is one of the four common phospholipids found in the plasma membrane of cells, the implications of this method of generating ceramide is that the cellular membrane is the target of extracellular signals leading to programmed cell death. There has been research suggesting that when ionizing radiation causes apoptosis in some cells, the radiation leads to the activation of sphingomyelinase in the cell membrane and ultimately, to ceramide generation.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.